arrow
E

Elena Verrecchia

università cattolica sacro cuore
H指数:19
被引数:1,415

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry

早期开始使用卡那奴单抗的斯蒂尔病患者长期缓解和单周期病程:国际AIDA网络登记数据

2026-09-291
PRE
Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network

卡那奴单抗在家族性地中海热中的完全疾病控制有效性和概率:AIDA网络的真实世界数据

2026-07-130
PRE
Case Report: Pleuro-myopericarditis in a frail older patient in an acute geriatric unit: the evidence gap in guideline-based therapy

病例报告:在急性老年病科中一位体弱老年患者的胸膜-心包-心肌炎:基于指南的治疗证据差距

2026-05-190
OAAI
Expanding the Therapeutic Landscape of Pericarditis: A Systematic Review of the Use of Conventional Immunosuppressants

扩展心包炎治疗领域的系统性综述:常规免疫抑制剂的应用

2026-05-050
OA
Long-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation

长期安全性结局及患者对居家静脉酶替代疗法(ERT)的偏好: Pompe病和Mucopolysaccharidosis Type I(MPS-I)两年观察的最终结果

2025-11-220
OA
Transition in inherited metabolic diseases: the dietitians, pediatricians and adult physicians' point of view: the results of an Italian survey

遗传代谢病中的过渡期:营养师、儿科医生和成人科医生的观点:一项意大利调查的结果

2025-05-220
OA
Duration of Disease and Long-Term Outcomes in Patients With Difficult-To-Treat Recurrent Pericarditis: A Chronic Condition Treated With Nonsteroidal Anti-Inflammatory Drugs, Colchicine, Corticosteroids, and Anti-Interleukin-1 Agents

难治性复发性心包炎患者的病程及长期预后:一种采用非甾体抗炎药、秋水仙碱、糖皮质激素及白介素-1抑制剂治疗的慢性疾病

2025-01-232
OAAI
Recurrent pericarditis in older adults: Clinical and laboratory features and outcome
2024-09-091
OA
Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA Network registries
2024-05-103
OAAI
Safety outcomes and patients' preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
2023-10-271
OAAI
The Autoinflammatory Diseases Alliance Registry of monogenic autoinflammatory diseases
2022-09-0914
OAAI
Multicenter, non-interventional, double cohort study to assess the safety of alglucosidase alfa and laronidase in real-world home infusion setting
2022-02-010
OAAI